The conference will take place in London on the 11th - 13th September. Early registration is rewarded so visit the event website for the latest early bird rates or email enquire@iqpc.co.uk<\/a> to find out more. <\/p>\n With cell and gene manufacturing activity on the rise, the race towards commercialisation of cell and gene products has already begun. Where technology innovations are pathing the way towards the development of these products, challenges surrounding scale up and closed system processing highlight areas that need focus so that cell and gene therapy products can be produced on an industrial scale. Pharma IQ will be addressing the key barriers and opportunities in enhancing the development of cell and gene therapies, with the focus on how manufacturing processes can be improved ready for the market boom! <\/p>\n About Pharma IQ <\/p>\n Pharma IQ has 100k+ members and is an international online community focusing on providing pharmaceutical professionals with knowledge, information and articles. Pharma IQ is dedicated to creating a learning environment for sharing ideas, best practices and solutions within the pharmaceutical community. To learn more visit http:\/\/www.cellgenemanufacturing.iqpc.co.uk<\/a> , or call us at +44(0)207-036-1300 <\/p>\n Media Contact: Rumina Akther, Trainee Marketing Manager, IQPC: rumina.akther@iqpc.co.uk<\/a> or call +44(0)207-036-1300 <\/p>\n Press are invited to attend this important industry summit, if you would like to a complimentary press pass please email Rumina Akther on rumina.akther@iqpc.co.uk<\/a> <\/p>\n SOURCE Pharma IQ <\/p>\n <\/p>\n Continue reading here:<\/p>\n Pharma IQ: Cell & Gene Therapy Manufacturing Summit - PR Newswire (press release)<\/a><\/p>\n","protected":false},"excerpt":{"rendered":" The conference will take place in London on the 11th - 13th September. Early registration is rewarded so visit the event website for the latest early bird rates or email enquire@iqpc.co.uk<\/a> to find out more. With cell and gene manufacturing activity on the rise, the race towards commercialisation of cell and gene products has already begun. Continue reading